A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the women's health study

Clinical Chemistry

Volumn 59, Issue 6, 2013, Pages 949-958

  Mazer, Norman A ^a   Giulianini, Franco ^b   Paynter, Nina P ^b   Jordan, Paul ^a   Mora, Samia ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN DEFICIENCY;

APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; FEMALE; HUMANS; LIPOPROTEINS, HDL; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, THEORETICAL; PARTICLE SIZE; WOMEN'S HEALTH;

EID: 84878457545     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.196949     Document Type: Article

References (38)

1. O'Connor PM, Naya-Vigne JM, Duchateau PN, Ishida BY, Mazur M, Schoenhaus SA, et al. Measurement of prebeta-1 HDL in human plasma by an ultrafiltration-isotope dilution technique. Anal Biochem 1997;251:234-40. (Pubitemid 27392683)
2. Barter PJ, Clay MA, and Rye KA. High density lipoproteins: the anti-atherogenic fraction. In: Barter PJ and Rye KA, eds. Plasma lipids and their role in disease. Amsterdam: Harwood Academic Publishers; 1999. p 85-107.
3. Kunitake ST, Mendel CM, Hennessy LK. Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J Lipid Res 1992;33:1807-16. (Pubitemid 23006657)
4. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56. (Pubitemid 46348533)
5. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57:392-410.
6. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981;665:408-19. (Pubitemid 11011381)
7. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002;48:171-80. (Pubitemid 34272531)
8. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999;145:227-38. (Pubitemid 29359129)
9. Brewer HB Jr. Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 2011;96:1246-57.
10. Mora S. Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation 2009;119:2396-404.
11. Shen BW, Scanu AM, Kézdy FJ. Structure of human serum lipoproteins inferred from compositional analysis. Proc Natl Acad Sci U S A 1977;74:837-41. (Pubitemid 8068697)
12. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-70. (Pubitemid 44716510)
13. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119:931-9.
14. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, Miyauchi K. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995;41:717-23.
15. Casella G, Berger RL. Statistical inference. Pacific Grove (CA): Wadsworth and Brooks/Cole Advanced Books and Software; 1990. p 581-94.
16. Yamashita S, Hui DY, Wetterau JR, Sprecher DL, Harmony JA, Sakai N, et al. Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates highdensity lipoprotein concentration and composition. Metabolism 1991;40:756-63.
17. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15. (Pubitemid 38477775)
18. Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J 2012;163:515-21, 521.e1-3.
19. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.
20. Krauss RM, Wojnooski K, Orr J, Geaney JC, Pinto CA, Liu Y, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res 2012;53:540-7.
21. Scanu AM, Kruski AW. The chemistry of serum lipoproteins. In: Abraham S, ed. Pharmacology of lipid transport and atherosclerotic processes. International encyclopedia of pharmacology and therapeutics, section 24. Oxford: Pergamon Press Ltd; 1975. p 21-38.
22. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994;14:707-20.
23. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589-97. (Pubitemid 17026647)
24. Miller NE, Rajput-Williams J, Nanjee MN, Samuel L, Albers JJ. Relationship of high density lipoprotein composition to plasma lecithin:cholesterol acyltransferase concentration in men. Atherosclerosis 1988;69:123-9. (Pubitemid 18018603)
25. Fournier N, Atger V, Cogny A, Vedie B, Giral P, Simon A, et al. Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system. Atherosclerosis 2001;157:315-23. (Pubitemid 32710010)
26. Kimak E, Hałabiś M, Baranowicz-Gaszczyk I. Relationships between serum lipid, lipoprotein, triglyceride-rich lipoprotein, and high-density lipoprotein particle concentrations in post-renal transplant patients. J Zhejiang Univ Sci B 2010;11:249-57.
27. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-74. (Pubitemid 44394906)
28. Duverger N, Rader D, Duchateau P, Fruchart JC, Castro G, Brewer HB Jr. Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma. Biochemistry 1993;32:12372-9. (Pubitemid 23357957)
29. Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011;18:416-22.
30. Vuorela T, Catte A, Niemelä PS, Hall A, Hyvönen MT, Marrink SJ, et al. Role of lipids in spheroidal high density lipoproteins. PLoS Comput Biol 2010;6:e1000964.
31. Niesor EJ. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol 2011;22:288-95.
32. Grundy SM, Vega GL, Otvos JD, Rainwater DL, Cohen JC. Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men. Genetic and pharmacological evidence. J Lipid Res 1999;40:229-34. (Pubitemid 29069796)
33. Asztalos BF, Schaefer EJ. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003;91:12E-17E. (Pubitemid 36385070)
34. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012;60:508-16.
35. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42.
36. Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Stroes ES, Kastelein JJ, et al. Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. Clin Chem 2010;56:789-98.
37. Paynter NP, Sesso HD, Conen D, Otvos JD, Mora S. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin Chem 2011;57:1178-87.
38. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010;59:1153-60.